Project Title: |
AD(H)PKD - Evaluating ADPKD in the era of tolvaptan |
Project Type: |
Registry Adjunct biobank: DNA, Serum, Urine |
Disease group(s): |
AD structural kidney disorders |
Project Summary: |
Approval of Tolvaptan in Europe by the EMA as the first targeted therapy of autosomal-dominant polycystic kidney disease (ADPKD) based on the findings of the TEMPO 3:4 trial is a milestone in the treatment of this disease. After the significant benefit on eGFR in TEMPO 3:4 and 4:4 more data on this therapy regarding crucial questions in the real-life setting would be highly valuable. In order to address these questions we set up AD(H)PKD - a prospective cohort study - in 2015 which is going to follow up ADPKD patients that are evaluated for a potential therapy with tolvaptan for 10 years. |
Lead principal investigator(s): |
Roman-Ulrich Mueller, Cologne Franziska Grundmann, Cologne |
Co-investigator(s): |
Thomas Benzing, Cologne Volker Burst, Cologne |
Project Period: |
11/2015 - 12/2027 |
Sponsors: |
Industry, Local resources |
Project web page: |
https://www.adpkd.org/ |
ClinicalTrials.gov: |
NCT02497521 |